Daidzein Augments Cholesterol Homeostasis via ApoE to Promote Functional Recovery in Chronic Stroke by Kim, Eunhee et al.
Neurobiology of Disease
Daidzein Augments Cholesterol Homeostasis via ApoE to
Promote Functional Recovery in Chronic Stroke
Eunhee Kim,1,2Moon-SookWoo,1 Luye Qin,1 ThongMa,1 Cesar D. Beltran,1 Yi Bao,1 Jason A. Bailey,3 XDale Corbett,4
XRajiv R. Ratan,1,2Debomoy K. Lahiri,3 and Sunghee Cho1,2
1Burke-Cornell Medical Research Institute, White Plains, New York 10605, 2Feil Family Brain and Mind Research Institute, Weill Cornell Medical College,
New York, New York 10021, 3Institute of Psychiatric Research, Department of Psychiatry, Neuroscience Research Center, Indiana University School of
Medicine, Indianapolis, Indiana 46202, and 4Heart and Stroke Foundation Canadian Partnership for Stroke Recovery, University of Ottawa and University
of Toronto, Ottawa, Ontario K1G 5Z3, Canada
Stroke is the world’s leading cause of physiological disability, but there are currently no available agents that can be delivered early after
stroke to enhance recovery. Daidzein, a soy isoflavone, is a clinically approved agent that has a neuroprotective effect in vitro, and it
promotes axongrowth inananimalmodel of opticnerve crush.The current study investigates the efficacyofdaidzeinonneuroprotection
and functional recovery in a clinically relevant mouse model of stroke recovery. In light of the fact that cholesterols are essential lipid
substrates in injury-induced synaptic remodeling, we found that daidzein enhanced the cholesterol homeostasis genetic program,
including Lxr and downstream transporters, Apoe, Abca1, and Abcg1 genes in vitro. Daidzein also elevated the cholesterol homeostasis
genes in the poststroke brain with Apoe, the highest expressing transporter, but did not affect infarct volume or hemispheric swelling.
Despite the absence of neuroprotection, daidzein improved motor/gait function in chronic stroke and elevated synaptophysin expres-
sion. However, the daidzein-enhanced functional benefits and synaptophysin expression were abolished in Apoe-knock-out mice, sug-
gesting the importance of daidzein-induced ApoE upregulation in fostering stroke recovery. Dissociation between daidzein-induced
functional benefits and the absence of neuroprotection further suggest the presence of nonoverlappingmechanismsunderlying recovery
processes versus acute pathology. With its known safety in humans, early and chronic use of daidzein aimed at augmenting ApoE may
serve as a novel, translatable strategy to promote functional recovery in stroke patients without adverse acute effect.
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Introduction
Improvements in acute stroke patient care have resulted in
reduced stroke mortality, leaving more survivors with severe
disability and a long road of recovery. Despite demands in devel-
oping potential strategies to aid functional recovery in stroke,
there is a paucity of medical treatments available to treat post-
stroke impairment and promote recovery. Studies showed that
stroke initiates metabolic and genetic changes that persist for
weeks to months following the initial insult (Carmichael, 2006;Received July 31, 2015; revised Sept. 11, 2015; accepted Oct. 12, 2015.
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Significance Statement
Therehavebeen recurring translational failures in treatment strategies for stroke.Oneunderlying issue is thedisparity inoutcome
analysis between animal and clinical studies. The former mainly depends on acute infarct size, whereas long-term functional
recovery is an important outcome in patients. In an attempt to identify agents that promote functional recovery, we discovered
that an FDA-approved soy isoflavone, daidzein, improved stroke-induced behavioral deficits via enhancing cholesterol homeo-
stasis in chronic stroke, and this occurs without causing adverse effects in the acute phase. With its known safety in humans, the
study suggests that the early and chronic use of daidzein serves as a potential strategy to promote functional recovery in stroke
patients.
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Nudo, 2007). However, understanding of the mechanism under-
lying the repair/restorative processes and identification of biolog-
ical targets in chronic stroke is largely limited.
Consumption of soy is associatedwith numerous health benefits
againstobesity, cancer, osteoporosis, cardiovasculardisease, and im-
mune deficiency (Orgaard and Jensen, 2008; Wenzel et al., 2008).
Daidzein, an isoflavone, is amajor component of soywith structural
similarity to estrogen. It exerts an anti-inflammatory effect, lowers
lipid levels, and increases mitochondrial biogenesis (Ricketts et al.,
2005; Rasbach and Schnellmann, 2008; Wang et al., 2008). As an
activator of nuclear receptor peroxisome proliferator-activated re-
ceptors (PPARs), daidzein enhances transcription of PPARs-
dependent genes, including liver X receptors (LXRs, Nr1h gene
family in mice). By heterodimerizing with retinoid X receptors
(RXRs), LXRs regulate the transcription of cholesterol transporter
genes,Apoe,Abca1, andAbcg1 (Whitney et al., 2002), either directly
or through sterol-independent regulatory element and enhancer
sites (Shih et al., 2000; Kennedy et al., 2001; Langmann et al., 2002).
The cholesterol transporters provide lipid substrates for
maintenance of membrane and synaptic integrity in normal and
injury-induced synaptic remodeling. Reduced availability of lipid
substrates is associated with neurodegenerative conditions,
whereas administration of endogenous steroids that enhance the
processes improves outcomes (Chen et al., 2011). ApoE is the
most abundant cholesterol transporter in the CNS and plays a
vital role in cholesterol homeostasis, neuronal repair, synaptic
plasticity, and -amyloid peptide (A) clearance (Mahley and
Rall, 2000; Cramer et al., 2012). Although expressed less in the
CNS, Abca1 promotes cholesterol efflux by preferentially lipidat-
ing naive ApoE, whereas Abcg1 acts on partially lipidated ApoE
(Karten et al., 2006; W.S. Kim, et al., 2008). Notably, daidzein
upregulates the expression ofAbcg1 (Mezei et al., 2003; Gao et al.,
2008), and it promotes axonal outgrowth in cultured hippocam-
pal neurons via estrogen receptor signaling (Wang et al., 2008).
Previously, we reported that daidzein overcame the inhibition of
axonal outgrowth induced bymyelin-associated glycoproteins in
vitro and promoted regeneration of axons in an optic nerve crush
model in vivo (Ma et al., 2010). Furthermore, studies by others
reported that daidzein exerted neuroprotection in oxygen-
glucose deprived conditions (Hurtado et al., 2012) and enhanced
recovery in rats following stroke (Hurtado et al., 2012; Stout et al.,
2013). Because daidzein is a fairly safe agent that has been widely
consumed as a soy component, we investigated whether daidzein
is a potential neuroprotective and recovery agent in stroke and
underlying events that are associated with these benefits. Here we
report that daidzein, without affecting infarct size, promoted
functional recovery via enhancing the cholesterol homeostasis
program with Apoe being a critical component.
Materials andMethods
Study design. Experiments were performed with in vitro culture systems
and in vivo using mice. For in vitro studies, three independent experi-
ments were performed with duplicated samples at a given drug concen-
tration. For in vivo studies, the use of animals and procedures was
approved by the Institutional Animal Care and Use Committee of Weill
Medical College of Cornell University and in accordance with the Insti-
tutional Animal Care and Use Committee, National Institutes of Health,
and ARRIVE guidelines. The number of animals was calculated a priori
by power calculation. Eleven animals per group were targeted to reach
power 0.83 at a significance level of 0.05 assuming 25% difference in
mean, a 20% SD at the 95% confidence level. Mice were randomized to
receive sham or middle cerebral artery occlusion (MCAO) surgery. In
certain cases, surgeons could not be blinded to the identity of groups at
the time of surgery due to higher body weight or phenotype associated
with Apoe knock-out (KO) mice. Mice were randomly selected by draw-
ing different colored balls to receive vehicle or daidzein. The identity of
the drug was concealed (coded A or B) by a third party and administered
to animals blinded to experimenters. Because of the chronic nature of the
study, each animal received a tattoo and their identity and treatment
were blinded to the persons who assessed injury size and performed the
behavior tests.
Cell cultures.HT22murine hippocampal cells were cultured inDMEM
with 4500 mg/dl glucose (Sigma-Aldrich), L-glutamine, and pyridoxine
hydrochloride. C8-D1A immortalized mouse astrocyte cells (CRL-2541,
American Type Culture Collection) were cultured in the DMEM. These
cultures were supplemented with 10% FBS (Mediatech), 100 IU penicil-
lin and 100g/ml streptomycin (Invitrogen) at 37°C in a humidified 5%
CO2 incubator.
Primary neuron-enriched cultures were generated from the papain
digestion of cortical tissue harvested from E14.5 embryos of C57 mice.
The resulting cells were plated at a density of 1.04  105 cells/cm2 in
6-well plates in Neurobasal media supplemented with 2% B27, 0.5 mM
glutamine, and penicillin/streptomycin. After 1 d in culture, the cells
were maintained in media containing 10 M 5-fluoro-2-deoxyuridine
to kill off non-neuronal cells. The cells were treated after 7 DIV with
media lacking mitotic inhibitors and consisted of99% neurons as as-
sessed by MAP2 and GFAP immunocytochemistry (data not shown).
For astrocyte cultures, cortical tissue was harvested from postnatal day 1
mice, digestedwithpapain, andplated at 1.5103 cells/cm2 in 6-well plates
in MEM (Mediatech) supplemented with 10% horse serum and penicillin/
streptomycin. After the astrocytes reached confluency (2 weeks), the cul-
tures were treated with 8M cytosine-D-arabinofuranoside for 3 d to kill off
contaminating nonastrocyte cells (Haskew-Layton et al., 2010).
Daidzein and T0901317 treatment in vitro culture. Neurons and astro-
cytes at 7 and 14 DIV, respectively, were treated with daidzein
(Sigma-Aldrich) and T0901317 (Tocris Bioscience). The indicated con-
centrations of daidzein and T0901317 were added in the culture media
with the absence of mitotic inhibitors. Twenty-four hours later, mRNA
was harvested using TRI Reagent (Molecular Research Center) and pu-
rified using the Direct-zol RNA MiniPrep kit (Zymo Research) with
in-column DNaseI digestion.
ApoE promoter activity assay. U373 human glioblastoma cells were
maintained inMEM, supplementedwith 10%FBS (AtlantaBiologicals) and
an antibiotic-antimytoticmixture (Mediatech). Thedaybefore transfection,
cells were transferred to 96-well plates at a density of 50,000 cells per well.
Cells were transfected with either the pGL3-Basic vector (Promega) or the
pGL3 vector containing 1.1 kb of the 5 upstream regulatory promoter re-
gion of the humanApoE gene controlling expression of the firefly luciferase
reporter gene (hAPOE1.1). Cells were simultaneously transfected with 285
ng of the pGL3-based plasmid (vector or hAPOE1.1) and 15 ng of the
pRLSV40 plasmid (Promega) expressing renilla luciferase under the consti-
tutive SV40 promoter as an internal control. Plasmid DNA was transfected
into the cells using 0.75 l per well of the Transfectin transfection reagent
(Bio-Rad) in serum- and antibiotic-freemedium. Two hours after transfec-
tion, cells were treated with vehicle or the indicated concentrations of daid-
zein in MEM containing 10% FBS and antibiotics for 48 h with n 6 per
treatment. Cells were then lysed, and both firefly and renilla luciferase activ-
ities weremeasured using theDual Luciferase kit (Promega), per themanu-
facturer’s instructions. Results are expressed as the ratio of firefly/renilla
luciferase activity. Toxicitywas evaluatedby a lactate dehydrogenase enzyme
activity assay kit, per the manufacturer’s instructions (Sigma-Aldrich).
Animals.Experimentswere performed in 10- to 11-week-oldmaleC57
(C57 bl/6) and Apoe KO (C57 background) mice purchased from The
Jackson Laboratory. Themice were housed at the institute’s animal facil-
ity, which maintained temperature, humidity, and 12 h light/dark cycle.
Amaximumof 5micewas housed in a cagewith an individual ventilating
system and irradiated bedding (1/8" Bed O’s Cobs, Anderson). Sterilized
food (PicoLab Rodent diet 5053, LabDiet) and water were freely accessi-
ble in their cage.
Acute and stroke recovery models and daidzein treatment. Transient
MCAO was performed in mice according to previously described meth-
ods (E. Kim et al., 2012; Qin et al., 2014). Mice were anesthetized with
isoflurane (5% induction and 1.5%–2.0% maintenance) with a mixture
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of oxygen and nitrogen (30%/70%). A 6-0 Teflon-coated black monofil-
ament surgical suture (Doccol) was inserted into the exposed external
carotid artery, advanced into the internal carotid artery, andwedged into
the circle of Willis to obstruct the origin of the MCA and transiently
occlude for 30 min. Cerebral blood flow was continuously monitored 15
min before stroke, during 30 min MCAO and 15 min of reperfusion by
Laser-Doppler flowmetry (Periflux System 5010; Perimed). Mice were
then placed in a recovery cage until the animal regained consciousness
and resumed activity. Using a rectal probe controlled byMasterflex water
pump on an operating table and thermistor temperature controller
(Cole-Parmer), animal’s body temperatures were maintained at 37 
0.5°C during entire surgical procedures and recovery after the surgery.
The mice were then returned to their home cages where they were pre-
viously housed together. Buprenorphine, lidocaine, and buprivacaine
were administered during postischemia as analgesics. Inclusion and ex-
clusion criteria for mice were based on the severity of ischemia. Animals
exhibiting reduced cerebral blood flow 80% during MCAO and re-
stored cerebral blood flow80% by 10 min following reperfusion were
included in the study.
Our proximalMCAO by an intraluminar threadmethod produced an
infarct 40 mm3 (30% of a hemisphere) and mostly confined to the
striatumwith incidental damage in somatosensory cortex. The size of the
basal ganglia in the rodent brain as a proportion of total brain volume is
approximately twofold higher than that in the human brain (Swanson,
1995). Therefore, subcortical infarcts produced by these methods would
be approximately twofold larger than those in humans when anatomical
proportions between the species are considered. As subcortical stroke in
human ranges from 4.5% to 14% of a hemisphere (Carmichael, 2005),
the current mouse strokemodel generates proportionally similar magni-
tude of subcortical injury as human subcortical stroke.
For long-term stroke recovery, mice received moxifloxacin (100 mg/
kg) for 3 d. The prophylactic antibiotic treatment was shown to effec-
tively reduce mortality in an animal model of stroke by attenuating
peripheral infection (Meisel et al., 2004). In addition, saline was subcu-
taneously administered daily, and hydrogel (Clear H2O) was given to
prevent dehydration. With the implementation of poststroke care (anti-
biotic regimen, rehydration, and feeding hydrogels with soft diet) during
the acute period (1 week), mice start to regain their body weight by day
5 and continue to recover from stroke. Animals were randomly selected
for vehicle or daidzein treatment. Vehicle or daidzein (10 mg/kg, Sigma-
Aldrich) was administered subcutaneously within 30 min of reperfusion
after confirming the reperfusion of blood flow, daily for 7 d and then
every other day up to 1 month.
Tissue preparation. Brains were excised, frozen, and sectioned using an
unbiased stereological sampling strategy to reflect the MCA territory in
both hemispheres as previously described (E. Kim et al., 2014). Tissue
sections with 30 m thicknesses were collected serially at 600 m inter-
vals for analysis of infarct volume and immunohistochemistry. Sections
in between were cut in half and collected for each hemisphere to deter-
mine mRNA and protein levels.
Measurement of infarct volume and hemispheric swelling. Serial sections
representing the entireMCA territory were subjected to a phase-contrast
microscope to visualize infarcted area. Infarct volume was determined
using Axiovision software (Carl Zeiss). For edema assessment during
acute phase, percentage hemispheric swelling (%HS) is calculated from
the difference in volume between two hemispheres and then divided
by contralateral hemisphere volume according to a formula: %HS 
[(ipsilateral volume 	 contralateral volume)/contralateral volume] 
100 (Lin et al., 1993). At 4 weeks after ischemia, noninjured, scar, and
contralateral tissue volumes were measured, and infarct volume was es-
timated by subtracting the remaining ipsilateral volume from contralat-
eral volume.
Real time RT-PCR. Relative mRNA levels were quantified with real-
time RT-PCR using fluorescent TaqMan technology as described pre-
viously (E. Kim et al., 2012, 2014). Total RNA from brain tissues or
cell line cultures was reverse transcribed using QuantiTech reverse
transcription kit (QIAGEN), according to the manufacturer’s proto-
col. PCR primers and probes specific for the genes in this study were
obtained as TaqMan predeveloped assay reagents for gene expres-
sion (Invitrogen). Primers used were Ppar (Mm00440945_m1); Lxr
(Nr1h) (Mm00443451_m1); Scarb1 (Mm00450236_m1); Ldlr (Mm0
0440169_m1); Abcg1 (Mm00437390_m1); Abca1 (Mm01350760_m1);
Apoe (Mm00437573_m1); Lrp1 (Mm00464608_m1); Synaptophysin
(Mm00436850_m1); Gap43 (Mm00500404_m1); Psd95 (Mm00492
193_m1);Gfap (Mm00546086_m1);Arginase-I (Mm00475988_m1);Fas
(Mm00662319_m1); Lpl (Mm00434764_m1); Srebp1 (Mm00550
338_m1); -actin (Mm00607939_s1). -Actin was used as an internal
control for normalization of samples. The PCR was performed using
FastStart Universal Probe Master Mix (Roche) in an Applied Biosystems
7500 Fast Real-Time PCR system (Invitrogen), according to the manu-
facturer’s instructions. For primary astrocyte and neuron cultures, 40 ng
RNA was assayed directly using the ABI One-step RNA-to-Ct master
mix. The results were analyzed by 7500 Fast Real-Time PCR System
software (Invitrogen).
Western blot analyses.Consistentamountsof totalprotein (2g forApoE
and synaptophysin assays; 10 g for PSD-95 assay) were loaded on a Nu-
PAGE4%–12%Bis-TrisGel (Invitrogen) and transferredontoPVDFmem-
brane (Bio-Rad). Themembranewas incubated in blocking buffer (Li-Cor)
for 1 h followedbyApoE (sc-8384, SantaCruzBiotechnology), synaptophy-
sin (ab8049, Abcam), PSD-95 (51-6900, Invitrogen), or GAPDH (sc-25778,
Santa Cruz Biotechnology) antibody in blocking buffer (1:1000) at 4°C. The
membrane was washed with Tris-buffered saline containing 0.05% Tween
20 followed by incubating with appropriate secondary antibodies conju-
gated with AlexaFluor-680 (A 21088, Invitrogen), IRDye 800CW (926-
32212, Li-Cor), or IRDye 680RD (926-68071, Li-Cor) in blocking buffer for
1 h. Then each protein’s specific band was visualized using the Odyssey
Imaging System(Li-Cor). Specificity of bandswas confirmed in tissues from
ApoeKOmice (for ApoE band) and/or by omitting primary antibody incu-
bation. Western blots were performed in multiple gels. To normalize inter-
blot variability, identical samples were loaded in each blot as internal
controls, and the density of the internal standard sample (normalized by
GAPDHor-actin)wasused to standardize other samples inmultiple blots.
Immunohistochemistry.Mice (n 2 or 3/group) were perfusion-fixed,
and immunohistochemistry was performed for visualization of protein
localization, according to the method previously described (Qin et al.,
2014). Brains were sectioned coronally in a cryostat (thickness, 40 m)
and incubated overnight with the following primary antibodies: GFAP
(astrocytes marker, 1:3000; EMD Millipore), ApoE (1:000; Abcam),
MAP-2 (neuronal marker, 1:3000, Abcam), followed by incubation with
appropriate secondary antibodies conjugated with AlexaFluor-488 or
-594 (1:200; Invitrogen) for 1 h at room temperature. Specificity of the
staining was confirmed in the brain section from Apoe KO mice (for
ApoE) and omitting primary antibody incubation. Sections were washed
with PBS between incubations and examined under a florescent micro-
scope or laser scanning confocal microscopy (Carl Zeiss).
Behavior tests. Motor and gait functions were longitudinally assessed
by a rotarod (Med Associates) and Noldus Catwalk XT gait analysis
system (Noldus InformationTechnology), as previously reported (Qin et
al., 2014). For rotarod test, mice were placed on a rod of rotarod device,
which was set to accelerate from 4 to 40 rpm over the course of 5 min.
After 1 week of daily pretraining, the latency to fall from the rod was
averaged from five trials. For Catwalk, mice were pretrained daily for 2
weeks to cross an illuminated glass walkway 3 consecutive times and then
at intervals during the poststroke period. The images from each trial that
consisted of 3 consecutive runs were converted into digital signals. Each
footprint was classified as a left front (LF), left hind (LH), right front
(RF), and right hindpaw (RH). After the classification, a priori selected
gaits parameters that are relevant to the kinematics of stroke recovery
were analyzed: spatial parameters based on individual paws (mean inten-
sity), relative position betweenpaws (stride length), temporal parameters
(swing speed, walk speed), and parameter related to interlimb coordina-
tion (regularity index).
Data analyses. Infarct volume and%HS were reported as mean95%
CIs. All other data were reported as mean SEMGene expression levels
from in vivo studies were presented as the -actin normalized value
according to the formula, Value  2(-actin threshold cycle-target
gene’s threshold cycle). Gene expression levels in in vitro studies were
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reported relative to control cultures and averaged from three indepen-
dent experiments.
Statistics. Comparison between two groups was statistically evaluated
using Student’s t test. Multiple comparisons were made using ANOVA
followed by post hoc tests. For gene/protein expression, analyses in cul-
tures and the brain were performed by one-way and two-way ANOVA,
respectively, followed by post hocNewman–Keuls tests. For gait analyses,
two-way ANOVAwith Bonferroni correction was used. Differences were
considered significant at p 0.05.
Results
Daidzein increases Lxr, Apoe, Abca1, and Abcg1 gene
expression in vitro
The effect of daidzein on the transcription of genes involved in
cholesterol homeostasis, including Lxr and downstream trans-
porters Apoe, Abca1, and Abcg1, was assessed in primary cortical
neurons and astrocytes. Daidzein increased expression of Lxr, a
PPAR-dependent gene, more robustly in neurons than astro-
cytes (Fig. 1A,B). In astrocytes, daidzein treatment significantly
elevatedAbca1 andApoe (Fig. 1D,H), but notAbcg1mRNA (Fig.
1F). Treating the cultures with T0901317, an LXR agonist,
showed expected increases in expression of Lxr downstream
transporter genes (Fig. 1C–H) but not its own expression (Fig.
1A,B). T0901317 also increased sterol-regulatory element bind-
ing proteins-1 (Srebp1) and its target genes, fatty acid synthase
(Fas) and lipoprotein lipase (Lpl) in astrocytes (Fig. 1 J,L,N).
Daidzein increased Srebp1 in neurons (Fig. 1I), without affecting
Fas and Lpl expression both in neurons and astrocytes (Fig. 1K–
N). We further determined transcriptional activity of APOE in
human glioblastoma U373 cells containing a 1.1 kb of human
APOE (hAPOE) promoter-luciferase plasmid (Maloney et al.,
2007). Incubation with different concentrations of daidzein,
from 5 to 100 M, increased APOE transcriptional activity (Fig.
1O). Lactate dehydrogenase levels in themedia in cultures treated
with various concentrations of daidzein were not different from
vehicle-treated cultures, excluding potential toxicity of daidzein
at the concentrations used (Fig. 1P). The findings show that daid-
zein induces the cholesterol homeostasis genetic program with-
out toxicity and inducing transcription of the lipogenic genes.
Stroke induces Lxr-downstream transporter gene expression
To address the relevance of the cholesterol homeostasis ge-
netic program in chronic stroke, we first determined temporal
changes in Lxr and transporter Abca1, Abcg1, and Apoe genes
in the acute and recovery phase of poststroked brain (Fig.
2A–D). While relatively constant in the contralateral hemi-
sphere, these genes were induced in the stroked hemisphere
Figure1. Daidzein increases cholesterol homeostasis programgenes in vitro.A–N, Gene expression in primary cortical neurons (A, C, E,G, I,K,M ) and astrocytes (B,D, F,H, J, L,N ) following the
incubation of daidzein (10, 20, 40, 80, 100M) or a LXR agonist, T0901317 (0.01, 0.1, 1, 5M) for 24 h. Lines indicate the expression level of each gene in cultures treatedwith vehicle for 24 h. *p
0.05 versus vehicle (one-way ANOVA, Newman–Keuls post hoc test). **p 0.01 versus vehicle (one-way ANOVA, Newman–Keuls post hoc test). ***p 0.001 versus vehicle (one-way ANOVA,
Newman–Keuls post hoc test).O,P, Effect of daidzein (Dz) on hAPOEpromoter activity indicated by the ratio of firefly/renilla luciferase activities (O) and LDH release (P) in U373humanglioblastoma
cells. n 6. Student’s t test. *p 0.05 versus Vector.
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during 1–4 weeks after stroke, followed by a return to baseline
at 2 months after stroke. Of these genes, Apoe was the most
abundantly expressed cholesterol transporter in the brain. The
basal level of Apoe transcripts (Apoe/Actin; 0.84  0.06, n 
4–6) was 50–100 times higher than those of Abca1
(0.0064  0.0002) and Abcg1 (0.013  0.007). ApoE protein
levels were noticeably elevated at 1 month after stroke but not
at day 3, reflecting corresponding protein expression at this
time (Fig. 2E). ApoE protein was predominantly localized in
astrocytes in the contralateral (Fig. 2H ) and rarely in the peri-
infarct region of stroked hemisphere (Fig. 2 I,N ). On the other
hand, ApoE staining was mostly absent in neurons in the con-
tralateral hemisphere (Fig. 2L) with some occurrence in the
peri-infarct area (Fig. 2M,N ), supporting a reported view on
cholesterol transport from astrocytes to neurons during neu-
ral repair following CNS injuries (Pfrieger, 2003).
Daidzein increases the stroke-induced cholesterol
homeostasis programwithout reducing infarct size
We initially assessed the effect of daidzein on multiple genes that
are involved in cholesterol homeostasis and synaptic remodeling
at day 3 after stroke. Ratios of stroke-induced mRNA levels over
those in the contralateral hemisphere (ipsilateral/contralateral)
in vehicle-treated group showed increased Lxr, Scarb1, Abca1,
and GfapmRNA and the gene induction patterns were similar in
daidzein-treated group (Fig. 3A; Table 1). For cholesterol ho-
meostasis genes, we found that stroke significantly increased Lxr
and Abca1mRNA (Fig. 3B,C) and decreased in Abcg1 and Apoe
genes (Fig. 3D,E). Among these genes, daidzein significantly in-
creased Lxr and Apoe in the ipsilateral hemisphere (Fig. 3B,E).
Both treatment groups displayed a similar degree of stroke sever-
ity indicated by comparable cerebral blood flow reduction during
ischemia (14.6  1.2 vs 14.1  0.9, n  25, not significant) and
reperfusion at 10 min after stroke (97.2 6.4% vs 118.2 7.3%,
not significant). Daidzein treatment neither increased nor de-
creased infarct size or edema (Fig. 3F), showing that daidzein has
no acute neuroprotective effect.
A possibility of daidzein-induced long-term neuroprotection
was assessed in mice treated with daidzein for 1 month. Ratios of
stroke-induced mRNA levels against the contralateral hemi-
sphere showed similar increases inLxr, Scarb1,Abca1,Apoe,Tsp2,
and Gfap mRNA in both vehicle and daidzein-treated groups
(Fig. 4A; Table 2). Compared with vehicle treatment, daidzein
significantly elevatedAbca1,Abcg1, andApoemRNAs at 1month
after stroke (Fig. 4B–E). For lipogenic genes, daidzein increased
stroke-induced Srebp1 mRNA without affecting Fas and Lpl ex-
pression (Table 2). ApoE protein was also significantly increased
at this time (Fig. 4F). There was no difference in expression of the
cholesterol homeostasis genes in age-matched shammice treated
with vehicle or daidzein for 1 month (data not shown). Because
Figure 2. Stroke induces cholesterol homeostasis program in the brain.A–D, Temporal gene profiles of Lxr (A), Abca1 (B), Abcg1 (C), and Apoe (D) in the poststroke brain at various postischemic
time points. mRNA levels in the contralateral and ipsilateral hemispheres were measured without stroke (Pre), and during acute (hours (h) to days (d)), subacute (d to weeks (w)), and long-term
recovery (week to months (m)) phases. y-axis represents mRNA normalized by actin. *p 0.05 versus contralateral (Student’s t test). **p 0.01 versus contralateral (Student’s t test). ***p
0.001versus contralateral (Student’s t test).E, ApoEprotein levels in thebrainof Pre, 3d, and1monthafter stroke (cropped imagesof original blots).Apoe	/	, brain tissue fromApoeKOmice, *p
0.05 (two-way ANOVA, followed by a Newman–Keuls post hoc test). ***p 0.001 (two-way ANOVA, followed by a Newman–Keuls post hoc test). F–M, Immunolocalization of ApoE in 1 month
poststroke brain. Double immunofluorescence labeling of ApoE (F ) with GFAP (G–I ) or ApoE (J ) with MAP2 (K–M ). Merged micrographs in the contralateral cortex (H, L), peri-infarct area in the
ipsilateral hemisphere (I,M ), F, Inset, No specific ApoE immunoreactivity in the brains fromApoeKOmice.N, GFAP-stained ipsilateral hemisphere. Square represents the peri-infarct area chosen for
I, M. n 2. Scale bars: I, 100m; N, 1 mm.
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stroke causes atrophy, brain volume representing noninjured tis-
sue, ischemic scar tissue, remaining total ipsilateral tissue, and
resorbed tissue (estimated infarct) were analyzed. We found no
differences in any of these region volumes (Fig. 4G), confirming
that daidzein-induced cholesterol homeostasis genetic program
uncouples with neuroprotection.
Daidzein improves motor/gait function following stroke
As cholesterol homeostasis is a critical event for injury-induced
repair and neural remodeling (Nudo, 2007), we next determined
the effect of daidzein on functional recovery. To obtain sensitive
and quantifiable functional data, behavior parameters that are
biologically meaningful and relevant to the kinematics of stroke
patients were chosen a priori for motor/gait function during
acute and recovery phases following stroke. Stroke-induced
changes in behavior were expressed as a percentage of the pre-
ischemia baseline to account for interanimal variability. Stroke
caused acute body weight reduction, which returned to baseline
1 month in both groups. The acute body weight loss was less in
daidzein-treated mice (Fig. 5A). Stroke caused acute and sus-
tained deficits in locomotion in rotarod performance (Fig. 5B)
and walking speed (Fig. 5C), which were improved by daidzein
Figure 3. Daidzein increases stroke-induced Lxr and Apoe mRNA without affecting acute brain injury. Following 30 min MCAO, mice were treated with daily subcutaneous administration of
vehicle (Veh) or daidzein (Dz, 10 mg/kg) for 3 d. A, Effect of daidzein on stroke-induced cholesterol homeostasis and synaptic plasticity genes in the vehicle (left) and daidzein (right) treated mice
at 3 d. Dotted lines indicate mRNA expression in contralateral hemisphere. y-axis represents ratios of ipsilateral over contralateral mRNA expression; n 5 or 6. B–E, Lxr (B), Abca1 (C), Abcg1 (D),
and Apoe (E) mRNA levels were measured in stroked brain; n 5 or 6. y-axis represents mRNA levels normalized by actin. *p 0.05 versus contralateral side (effect of stroke) (two-way ANOVA,
followedby aNewman–Keulspost hoc test). **p0.01 versus contralateral side (effect of stroke) (two-wayANOVA, followedby aNewman–Keulspost hoc test). ***p0.001 versus contralateral
side (effect of stroke) (two-way ANOVA, followed by a Newman–Keuls post hoc test). #p 0.05 versus Veh (effect of treatment) (two-way ANOVA, followed by a Newman–Keuls post hoc test). F,
Representative brain sections for infarct volume and percentage hemispheric swelling measurement at 3 d after ischemia (graph, mean 95% confidence interval); n 18/group.
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(indicated by #). Daidzein did not show benefit on the regularity
index, a measure of interlimb coordination that spontaneously
recovered by 2 weeks (Fig. 5D).
Several gait parameters for individual limbs were assessed in
LF, LH, RF, and RH limbs. Following stroke, all four limbs
showed sustained impairment in stride length (distance between
paw prints). Chronic daidzein administration significantly re-
duced the deficit in LF, LH, and RH limbs (Fig. 6A).While stroke
also caused sustained reduction in swing speed in all limbs in
both groups, daidzein attenuated the deficit in RH limb (Fig. 6B).
Similar to the regularity index shown in Figure 5D, daidzein did
not improve mean intensity, another spontaneously recovered
parameter (Fig. 6C). Overall, the results showed that daidzein
treatment improves motor/gait functions that showed sustained
deficit, but not gait parameters that were fully recovered, high-
lighting the efficacy of daidzein in a clinicallymeaningful context.
The functional benefits of daidzein treatment in the absence of
neuroprotection indicate that mechanisms underlying neuro-
protection unlikely overlap with recovery/repair processes. In
age-matched sham animals, chronic daidzein treatment did not
affect the longitudinal gait functions compared with those of
vehicle-treated group (data not shown).
ApoE deficiency abolishes daidzein-enhancedmotor/gait
function in stroke
As ApoE is the most abundant cholesterol transporter that was
elevated by daidzein in vivo, we addressed the importance of
daidzein-induced ApoE upregulation in functional recovery in
Apoe-knock-out (Apoe KO) mice. Stroke resulted in acute body
weight losses with subacute normalization by 2 weeks in vehicle-
treatedApoeKOmice. Chronic daidzein treatment did not atten-
uate acute body weight loss or improve rotarod performance
(Fig. 7A,B). Daidzein also provided no functional benefits in gait
functions (Fig. 7C–F). The only treatment effect (indicated by #)
observed in Apoe KO mice was the mean intensity in right RH,
where daidzein treatment resulted in a greater deficit (Fig. 7G).
Estimation of infarct volume by subtracting the ipsilateral from
contralateral volumes at 1 month after ischemia showed no dif-
ference between the groups (Veh vs Dz, 20.2 3.8 vs 25.8 4.0
mm3, not significant, n  13–14/group), confirming no detect-
able effect of daidzein on modulating infarct size. Treating Apoe
KOmice with daidzein increased Lxr and Abca1 gene expression
at 1 month after stroke, showing that the absence of ApoE does
not interfere with other cholesterol homeostasis genetic pro-
grams (Fig. 7H–J). Therefore, the findings suggest that daidzein-
induced ApoE upregulation is a critical component in fostering
functional recovery in chronic stroke.
ApoE is necessary for daidzein-induced synaptophysin
expression in chronic stroke
We then determined whether the daidzein-induced ApoE up-
regulation is necessary for induction of synaptic elements after
stroke. Chronic daidzein treatment in C57 mice selectively in-
creased synaptophysinmRNAwithout altering Psd-95 at 1month
after stroke (Fig. 8A,B). Further analyses between the presynaptic
and postsynaptic elements in C57mice showed significant corre-
lations between them in both hemispheres regardless of treat-
ments (Fig. 8E,F). Notably, daidzein resulted in higher
expression of synaptophysin at a given Psd-95 level in the ipsilat-
eral hemisphere with a significant slope difference between the
groups (p  0.001; Fig. 8F), showing selective elevation of the
presynaptic gene. Accordingly, there was a selective increase in
stroke-induced synaptophysin protein in the daidzein-treated
group (Fig. 8I). Compared with C57 mice, Apoe KO mice
showed an overall reduction of synaptophysin mRNA expres-
sion in both hemispheres (C57 vs Apoe KO, Contralateral,
0.19  0.02 vs 0.07  0.04; Ipsilateral, 0.18  0.09 vs 0.06 
0.0, n 8–10, p 0.001) and Psd-95 expression (C57 vs Apoe
KO, Contralateral, 0.10  0.008 vs 0.078  0.004; Ipsilateral
0.099  0.006 vs 0.064  0.008, n  8–10, p  0.05) (Fig.
8C,D). Daidzein treatment further reduced synaptophysin and
Psd-95 gene expression in Apoe KO mice (Fig. 8C,D). Synap-
tophysin and Psd-95mRNA levels were significantly correlated
in both hemispheres regardless of treatment (Fig. 8G,H ). Un-
like C57 mice shown in Figure 8F, I, the daidzein-induced
selective elevation of synaptophysin gene and protein in the
stroked hemisphere was absent in ApoE deficiency (Fig.
8H, J ). Together, the results showed that ApoE is necessary for
daidzein-induced synaptophysin expression in chronic stroke.
Discussion
Injury-induced repair and remodeling occur during critical peri-
ods following stroke. These processes provide a temporal window
in which augmentation of molecular and synaptic changes can
lead to behavioral adaptation/recovery. The current work identi-
fied daidzein as an enhancer of the genetic program governing
Table 1. Gene expression in the brain 3 d after strokea
Vehicle Daidzein
Contralateral Ipsilateral Contralateral Ipsilateral
Ppar  1.20E-03 9.9E-05 0.52E-03 6.0E-05b 1.41E-03 12.4E-05 0.69E-03 16.4E-05b
Lxr a 1.90E-03 9.7E-05 2.20E-03 7.1E-05b 2.12E-03 6.3E-05 2.58E-03 7.7E-05b,c
Scarb1  1.83E-03 1.1E04 4.79E-03 2.7E-04b 1.57E-03 2.3E-04 4.08E-03 6.2E-04b
Ldlr  5.63E-03 7.5E-04 4.03E-03 4.9E-04 5.44E-03 8.0E-04 3.84E-03 5.3E-04
Abcg1  7.32E-03 6.1E-04 4.74E-03 4.6E-04b 9.00E-03 7.2E-04 5.82E-03 6.7E-04b
Abca1  7.28E-03 3.5E-04 9.77E-03 3.7E-04b 7.07E-03 1.8E-04 10.07E-03 4.6E-04b
Apoe a 7.61E-01 3.3E-02 5.17E-01 1.5E-02b 8.97E-01 3.7E-02d 6.27E-01 4.6E-02b,c
Lrp1  8.99E-02 7.5E-03 6.61E-02 5.5E-03b 9.52E-02 2.9E-03 7.06E-02 6.5E-03
Synaptophysin  2.38E-01 1.1E-02 0.92E-01 1.2E-02b 2.70E-01 1.7E-02 1.44E-01 2.7E-02b
Gap-43  7.61E-02 3.0E-03 3.77E-02 4.1E-03b 7.85E-02 4.4E-03 4.45E-02 5.5E-03b
Psd-95  1.50E-01 1.2E-02 0.51E-01 0.7E-02b 1.47E-01 1.3E-02 0.73E-01 1.1E-02b
Gfap  2.57E-01 1.7E-02 3.77E-01 1.9E-02b 1.93E-01 5.0E-02 4.00E-01 4.5E-02b
aData are mean SEM. anda indicate no and significant gene changes in the ipsilateral hemisphere by daidzein treatment.
bp 0.05 versus contralateral (two-way ANOVA and post hoc Newman-Keuls test); n 5 or 6.
cp 0.05 versus ipsilateral of vehicle (two-way ANOVA and post hoc Newman-Keuls test); n 5 or 6.
dp 0.05 versus contralateral of vehicle (two-way ANOVA and post hoc Newman-Keuls test); n 5 or 6.
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cholesterol homeostasis and a potential stroke recovery agent.
The daidzein-induced benefits include increased expression of
genes that regulate the cholesterol homeostasis both in cultures
and poststroke brain, and enhanced motor/gait function during
the chronic recovery phase. Notably, the study revealed that
daidzein-induced ApoE upregulation is essential for enhancing
motor/gait functions and upregulation of synaptophysin, a pre-
synaptic element.
Literature shows that isoflavones, including daidzein, inhibits
HMG-CoA reductase, an enzyme for cholesterol biosynthesis
(Sung et al., 2004; Jung and Kim, 2013). Because daidzein was
known to activate PPAR, an upstream transcription factor of
Lxr, the study focused on the effect of daidzein on expression of
the genes involved in cholesterol homeostasis rather than its bio-
synthetic pathway. Not only Lxr and the downstream target
transporters were elevated in vitro, daidzein also elevated the cho-
Figure 4. Daidzein increases stroke-induced cholesterol homeostasis genes at 1 month without neuroprotection. Following 30min MCAO, mice were treated with daily subcutaneous adminis-
tration of vehicle (Veh) or daidzein (Dz, 10mg/kg) up to 7 d and then every other day up to 1month. A, Effect of daidzein on stroke-induced cholesterol homeostasis and synaptic plasticity genes in
the brain at 1 month after stroke in mice chronically treated with vehicle (left) and daidzein (right). Dotted lines indicate mRNA expression in contralateral hemisphere. y-axis represents ratios of
ipsilateral over contralateral mRNA expression; n 5 or 6. B–E, Lxr (B), Abca1 (C), Abcg1 (D), and Apoe (E) mRNA levels were measured in the stroked brain at 1 month after MCAO; n 8–11, F,
ApoEprotein levels in vehicle (Veh)- or daidzein (Dz)- treatedbrainat 1monthafter stroke.Apoe	/	, brain tissue fromApoeKOmice. *p0.05versus contralateral side (two-wayANOVA, followed
by a Newman–Keuls post hoc test). **p 0.01 versus contralateral side (two-way ANOVA, followed by a Newman–Keuls post hoc test). ***p 0.001 versus contralateral side (two-way ANOVA,
followed by a Newman–Keuls post hoc test). #p 0.05 versus Veh ipsilateral (two-way ANOVA, followed by a Newman–Keuls post hoc test). ###p 0.001 versus Veh ipsilateral (two-way ANOVA,
followedby aNewman–Keuls post hoc test).G, Assessment of tissue volume at 1month after ischemia. NI, Noninjured tissue (yellow); IS, ischemic scar tissue (red); T, total ipsilateral tissue (NI
IS);
EI, estimated infarct tissue calculated by subtracting total ipsilateral volume from total contralateral volume (i.e., difference between the hemispheres, green).
15120 • J. Neurosci., November 11, 2015 • 35(45):15113–15126 Kim et al. • Daidzein-Enhanced Stroke Recovery via ApoE
lesterol homeostasis genetic program in postischemic brainwhile
several other genes were relatively unaffected (Tables 1, 2). As
LXR is an important regulator of cholesterol and lipid metabo-
lism, the augmentation of cholesterol transporter expression via
LXR agonists was used to treat animal models of atherosclerosis
and stroke (Terasaka et al., 2003; Chen et al., 2010). However, the
LXR-directed approach stimulates transcription of Srebp1 and its
target genes Fas and Lpl. FAS and LPL are linked to the synthesis
of fatty acids and triglycerides, resulting in hypertriglyceridemia
and hepatic steatosis (Grefhorst et al., 2002; Chisholm et al.,
2003). Thus, an optimal therapeutic strategy would be to selec-
tively activate cholesterol efflux pathways without stimulating
Table 2. Gene expression in the brain 1month after strokea
Vehicle Daidzein
Contralateral Ipsilateral Contralateral Ipsilateral
Ppar  1.50E-03 1.6E-04 1.43E-03 1.1E-04 1.61E-03 0.7E-04 1.43E-03 1.5E-04
Lxr  1.95E-03 1.5E-04 2.26E-03 0.7E-04 1.83E-03 1.0 04 2.70E-03 1.8E04b
Scarb1  1.26E-03 0.8E04 2.13E-03 2.6E-04b 1.35E-03 1.1E-04 2.16E-03 1.4E-04b
Ldlr  4.65E-03 4.3E-04 5.11E-03 5.6E-04 4.78E-03 4.9E-04 5.21E-03 3.3E-04
Abcg1 a 1.51E-02 1.8E-03 1.54E-02 1.2E-03 2.07E-02 1.4E-03d 2.55E-02 1.7E-03b,c
Abca1 a 5.53E-03 2.4E-04 8.04E-03 5.7E-04 5.34E-03 4.4E-04 13.41E-03 21.1E-04b,c
Apoe a 7.87E-01 6.4E-02 11.65E-01 5.4E-02 8.17E-01 3.2E-02 17.12E-01 21.2E-02b,c
Lrp1  4.22E-02 4.1E-03 4.76E-02 3.8E-03 4.02E-02 3.1E-03 5.76E-02 4.4E-03b
Synaptophysin a 1.96E-01 2.0E-02 1.84E-01 1.1E-02 1.82E-01 0.9E-02 2.38E-01 1.1E-02b,c
Gap-43 s 1.67E-01 9.1E-03 1.79E-01 4.8E-03 1.40E-01 13.3E-03 1.36E-01 5.4E-03c
Psd-95  1.02E-01 9.2E-03 0.99E-01 6.8E-03 0.98E-01 3.9E-03 1.03E-01 5.7E-03
Gfap a 6.70E-02 4.0E-03 23.19E-02 23.7E-03b 8.07E-02 7.4E-03 33.46E-02 45.4E-03b,c
Fas  2.37E-02 2.3E-03 2.19E-02 1.7E-03 2.27E-02 1.1E-03 2.44E-02 1.1E-03
Lpl  1.06E-02 6.0E-04 1.31E-02 2.2E-03 1.01E-02 7.3E-04 1.62E-02 2.2E-03b
Srebp1 a 1.02E-03 9.1E-05 1.10E-03 10.1E-05 1.00E-03 5.2E-05 1.45E-03 9.6E-05b,c
aData are mean SEM.,a, ands indicate no and significant gene changes in the ipsilateral hemisphere by daidzein treatment.
bp 0.05 versus contralateral (two-way ANOVA and post hoc Newman-Keuls test); n 8–11.
cp 0.05 versus ipsilateral of vehicle (two-way ANOVA and post hoc Newman-Keuls test); n 8–11.
dp 0.05 versus contralateral of vehicle (two-way ANOVA and post hoc Newman-Keuls test); n 8–11.
Figure 5. Daidzein reduces stroke-induced body weight loss and improves behaviors. Longitudinal body weight measurement and behavior test were performed in vehicle (Veh) or daidzein
(Dz)-treated C57mice during acute and recovery phases. A, Percentage changes of body weight following ischemia. The stroke-induced body weight reduction was attenuated in daidzein-treated
mice during a critical period (3–6 d after stroke); n 22. *p 0.05 versus Veh. B, Rotarod performance before (pre) and during the 4 week (w) postischemic period, latency to fall measured in
seconds; n 9–11/group. C, D, Catwalk gait analyses: walk speed, the average speed expressed in distance units per second (C). Regularity index, a parameter to gauge the degree of interlimb
coordination (D). All behavior results are presented as percentage of preischemic baseline (% Pre, mean SEM); n 22 or 23/group. *p 0.05 (two-way ANOVAwith post hoc Bonferroni tests).
**p0.01versusPre (effect of stroke) (two-wayANOVAwithpost hocBonferroni tests). #p0.05, VehversusDz (effect of treatment) (two-wayANOVAwithpost hocBonferroni tests). ##p0.01,
Veh versus Dz (effect of treatment) (two-way ANOVA with post hoc Bonferroni tests).
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genes linked to lipogenesis (Kratzer et al., 2009). Compared with
T0901317, which upregulated Srebp1, Fas, and Lpl transcription
in primary astrocytes, daidzein increased Srebp1 transcription
without affecting the induction of Lpl and Fas genes in vitro (Fig.
1) and in the postischemic brain (Table 2). These findings suggest
a potential advantage of daidzein over T0901317 for chronic use
in stroke recovery.
The daidzein-induced functional benefits occurred in the ab-
sence of neuroprotection. Our previous in vitro data and litera-
ture suggested that daidzein, which has years of use in humans,
could possibly be neuroprotective and neurorestorative (Ma et
al., 2010; Hurtado et al., 2012). However, our current detailed in
vivo studies showed that while daidzein enhanced functional re-
covery, it neither increased nor decreased infarct size, consistent
with a study in rats (Stout et al., 2013). The dissociation of func-
tional recovery from neuroprotection indicates the presence of
repair process mechanisms that may be distinct from mecha-
nisms that underlie acute pathology/protection. The stage-
specific mechanisms reflect the anatomical distinction of the
tissues involved in different stages of chronic stroke. While acute
pathology involves the ipsilateral hemisphere, functional recov-
ery is thought to require plasticity from noninjured tissues
around the infarct and the contralateral hemisphere (Zeiler et al.,
2013; Qin et al., 2014). It is noteworthy that the same drug and/or
target may respond differently depending on the context of post-
stroke stages. For example, whereas an agent that inhibits stroke-
induced excessive tonic inhibition (net effect of excitation)
enhances stroke recovery, the treatment, if given too early (i.e.,
3 d after stroke), exacerbates acute stroke injury (Clarkson et
al., 2010). Thus, agents such as daidzein would allow treatment at
an early poststroke stage and provide a wider treatment window
for subsequent functional enhancement.
In the current study, daidzein treatment was initiated at the
early reperfusion period and continuously administered for 1
month. Several pharmacokinetic studies of chronic daidzein
treatment in both humans and rodents have shown increased
concentration of isoflavones in body fluids and tissues. With a
half-life of 6 h in humans and 12 h in rodents (King and
Bursill, 1998; Coldham and Sauer, 2000), chronic daidzein
administration was shown to be safe in clinical trials at a dose
of 0.5–1 mg/kg/d for 6 months (NCT00951912) or 12 months
(NCT01463436). Although the dose used in this study in mice
was higher (5–10 mg/kg/d) and the treatment duration was
shorter (1 month) than that used in the above clinical studies,
it was within the range of other rodent studies (0.1–50 mg/
kg/d) (Rivera et al., 2013; Soumyakrishnan et al., 2014). Im-
portantly, we found that chronic daidzein administration did
not increase injury size and hemispheric swelling (Figs. 3F,
4G). The absence of the adverse stroke outcomes in mice to-
gether with no evident toxicity in cultures (Fig. 1P) supports
safety of daidzein for early and long-term use in chronic
stroke.
Analysis of the motor/gait function in C57 mice revealed two
sets of behaviors that spontaneously recovered and ones with
sustained impairments (Figs. 5, 6). Daidzein improved the be-
haviors that showed sustained deficits (e.g., rotarod, speed, stride
length, and swing speed). On the other hand, the literature indi-
cates that unilateral stroke induces deficits in the limbs of both
sides, which has been described in rodent and human (Schaefer et
al., 2009; Darling et al., 2011; Pandian and Arya, 2013; Qin et al.,
2014). The observations suggest that the ipsilesional side was not
“nonaffected” but rather “less affected.” The underlying mecha-
nism that accounts for the acute bilateral deficits may include
plastic changes in the intact hemisphere and disturbed inter-
hemispheric connectivity, probably due to the ongoing injury in
the affected hemisphere that might be involved in the functional
impairments in the unaffected limbs (Gonzalez et al., 2004; van
Meer et al., 2010). Individual gait assessment in this study re-
vealed that the stroke-induced bilaterally deficits and daidzein
treatment resulted in bilateral enhancement (Fig. 6). Because an-
imals were subjected to unilateral right MCAO, improved func-
tion in the less affected limb (e.g., RH) suggests a potential role of
the contralesional hemisphere in functional recovery (Qin et al.,
2014). Relevantly, we observed that daidzein increased Apoe
mRNA at 3 d in the contralateral hemisphere (Fig. 3E; Table 1),
suggesting an intriguing possibility that this early rise in Apoe
Figure 6. Daidzein improves gait functions. Longitudinal behavior tests were performed in vehicle (Veh) or daidzein (Dz)-treated C57 mice during acute and recovery phases. A–C, Gait
parameters for individual limb in LF, LH, RF, and RH limbs. Stride length (A), swing speed (B), andmean intensity (C). All behavior results are presented as percentage of preischemic baseline (%Pre,
mean SEM); n 22 or 23/group. *p 0.05 (two-way ANOVAwith post hoc Bonferroni tests). **p 0.01 (two-way ANOVAwith post hoc Bonferroni tests). ***p 0.001 versus Pre (effect of
stroke) (two-way ANOVA with post hoc Bonferroni tests). ##p 0.01, Veh versus Dz (effect of treatment) (two-way ANOVA with post hoc Bonferroni tests). ###p 0.001, Veh versus Dz (effect of
treatment) (two-way ANOVA with post hoc Bonferroni tests).
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mRNA in the contralateral hemisphere may cause subsequent
benefits in stroke recovery.
There is no reported deficit in neurocognitive and retinal
function in a human subject lacking functional APOE gene
expression (Mak et al., 2014). In agreement with this clinical
finding, ApoE deficiency in mice did not affect baseline behav-
iors in this study (preischemic rotarod C57 vs Apoe KO, 253
49.4 s, 222.8 48.1 s, n 19, notsignificant). In addition, we
have previously shown that the infarct size and hemispheric
swelling were similar in WT versus Apoe KO mice (E. Kim et
al., 2008). This study, however, revealed a critical role of ApoE
in injury paradigm. Following stroke, Apoe KO mice treated
with daidzein did not display functional gains, even though
daidzein significantly increased Lxr and Abca1 mRNA levels
(Fig. 7). Thus, in the absence of the ApoE gene, Abca1 and Lxr
were inadequate to produce functional benefits, indicating a
necessary role for ApoE in fostering daidzein-promoted func-
tional recovery.
Because of its reduced capacity for lipidation and efflux of
cholesterol and phospholipids, APOE4 has been linked to a
high risk of developing Alzheimer’s disease (AD) (Michikawa
et al., 2000; Hanson et al., 2013). Because ApoE expression
level is a risk factor for AD regardless of APOE4 allele status
(Maloney et al., 2010), enhancing ApoE and other cholesterol
transporter expression by activating LXRs and RXRs has been
suggested as a way to improve AD pathology (Mandrekar-
Colucci and Landreth, 2011; Cramer et al., 2012; Boehm-
Cagan and Michaelson, 2014). The current study provides the
mechanistic evidence of ApoE for daidzein-induced func-
tional benefits and synaptophysin upregulation. Of particular
interest, in light of our functional daidzein results is that
APOE4 presence predicted age-related gait speed decline in
men (Verghese et al., 2013). Likewise, the presence of the
APOE4 allele is associated with reduced short- and long-term
recovery from stroke (Cramer and Procaccio, 2012). Our
working model is daidzein-induced upregulation of Lxr and
Figure 7. Daidzein-induced functional benefits are absent in ApoE deficiency. Longitudinal behavior test results in vehicle (veh) and daidzein (Dz)-treated Apoe KO mice during acute
and chronic recovery phases. A, Percentage changes of body weight following ischemia. Note the similar weight reduction in both groups during a critical period (3– 6 d poststroke); n
10 –12/group. B, Rotarod performance before (pre) and during the postischemic period up to 4 weeks (w), latency to fall measured in seconds; n 11/group. C, D, Catwalk gait analyses:
Walk speed, the average speed expressed in distance units per second (C). Regularity index, a parameter to gauge the degree of interlimb coordination (D). E–G, Catwalk gait parameters
for individual limb in LF, LH, RF, and RH. Stride length (E), swing speed (F ), and mean intensity (G). All behavior results are presented as percentage of preischemic baseline (% Pre,
mean SEM); n 10 –13/group for gait analysis. *p 0.05 versus Pre (effect of stroke) (two-way ANOVA with post hoc Bonferroni tests). **p 0.01 versus Pre (effect of stroke)
(two-way ANOVA with post hoc Bonferroni tests). ***p 0.001 versus Pre (effect of stroke) (two-way ANOVA with post hoc Bonferroni tests). #p 0.05, Veh versus Dz (effect of
treatment) (two-way ANOVA with post hoc Bonferroni tests). H–J, mRNA levels in the 1 month poststroke brain of Apoe KO mice, Lxr (H ), Abca1 (I ), and Abcg1 (J ); n 10 –13/group.
*p 0.05 versus contralateral side (two-way ANOVA and post hoc Newman–Keuls test). **p 0.01 versus contralateral side (two-way ANOVA and post hoc Newman–Keuls test).
***p 0.001 versus contralateral side (two-way ANOVA and post hoc Newman–Keuls test). #p 0.05 versus Veh ipsilateral (two-way ANOVA and post hoc Newman–Keuls test). ##p
0.01 versus Veh ipsilateral (two-way ANOVA and post hoc Newman–Keuls test).
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transporter genes provide a larger substrate base for conven-
tional cholesterol effusion.
The required ApoE for daidzein-induced synaptophysin
upregulation suggests mechanisms for cholesterol uptake into
neurons. Low-density lipoprotein-related receptor protein-1
(LRP1) is an ApoE receptor that involves receptor-mediated
endocytosis for cholesterol transport. Notably, we found that
Lrp1mRNA level in the brain was high in the ipsilateral hemi-
sphere at 1 month after stroke (10-fold higher than low-
density lipoprotein receptor gene Ldlr; Table 2). Correlation
analyses showed that stroke-induced Lrp1 expression is signif-
icantly correlated with Apoe (r 2 0.399, p 0.05, n 8) and
synaptophysin mRNA (r 2  0.432, p  0.05, n  8) in a
daidzein-treated group, but not in a vehicle-treated group.
Although there was no significant correlation between Apoe
and synaptophysin mRNA levels, the correlation slope in
daidzein-treated group was significantly elevated (p  0.01,
n  8). Therefore, it is unlikely that ApoE directly regulates
synaptophysin transcription in the presence of daidzein, but
rather through LRP1 for ApoE uptake for synaptophysin ex-
pression. Thus, daidzein is likely promoting the directional
movement of cholesterol through LRP1 in the injured brain
for neurite outgrowth for plastic changes.
Through the gain and loss of ApoE coupled with molecular
and functional studies, the current study demonstrated that
daidzein-induced ApoE is critical for functional recovery in
chronic stroke. The caveat of the study is a need to provide
relevance of the preclinical findings in mice to human pa-
tients. Nevertheless, the similarities in the anatomical organi-
zation of lumbar pattern generators and locomotor control
mechanisms between humans and rodents (Gerasimenko et
al., 2008) suggest shared mechanisms in locomotor/kinematic
recovery following stroke. As walking speed is one of the best
determinants of community ambulation and of high priority
to patients in the immediate aftermath of a paralytic stroke,
our findings of better locomotion, faster gait speed, larger
stride length and swing speed at the system levels, together
with elevated ApoE and synaptophysin expression at the cel-
lular level, provide a biological rationale for strategies aimed at
augmenting ApoE for stroke recovery. With its known safety
in humans, early and chronic use of clinically approved daid-
zein to aim at ApoE upregulation without having adverse ef-
fect on infarct size may serve as a novel, translatable strategy to
promote recovery in stroke patients. Moreover, the findings
should serve to catalyze additional studies on the association
Figure 8. ApoE is necessary for daidzein-induced synaptophysin expression in chronic stroke. Presynaptic and postsynaptic marker expression at 1 month after stroke in C57 (left, A,
B, E, F, I ) and Apoe KO (right, C, D, G, H, J ) mice. A–D, Synaptophysin and Psd-95 mRNA levels in C57 (A, B) and Apoe KO (C, D) mice. y-axis represents mRNA levels normalized by actin.
**p 0.01 versus contralateral side (two-way ANOVA and post hoc Newman–Keuls test). ***p 0.001 versus contralateral side (two-way ANOVA and post hoc Newman–Keuls test).
#p  0.05 versus Veh ipsilateral side (two-way ANOVA and post hoc Newman–Keuls test). E–H, Correlation between Synaptophysin (Syn) and Psd-95 gene expression in the C57
contralateral (E) and ipsilateral (F ) hemisphere and Apoe KO contralateral (G) and ipsilateral (H ) hemisphere. ***p 0.001, slope difference between Veh- and Dz-treated groups. I, J,
Synaptophysin (SYN) and PSD-95 protein expression in C57 (I ) and Apoe KO (J ) mice. n 8 –12/group for both genotypes. *p 0.05 versus contralateral side (two-way ANOVA and post
hoc Newman–Keuls test). C, Contralateral; I, ipsilateral.
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of prevalent ApoE isoforms with outcomes following stroke in
humans.
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